abstract |
The present invention relates to an improved method for treating fibrotic or fibroproliferative disorders. Combination therapies comprising a combination of one or more fibrocyte suppressors and one or more fibrosis-inducing factor antagonists or antifibrotic agents are provided. In one aspect, the method of the present invention is directed to fibrocytes such as serum amyloid P (SAP), IL-12, laminin-1, anti-FcγR antibody capable of cross-linking FcγR, aggregated IgG, cross-linked IgG and / or combinations thereof. Can be performed using inhibitors. |